Xeris Biopharma to retire 69% of convertible debt through $23M note exchange for cash and stock

Filed June 11, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

• high

  Company exchanging $23M of its 8% convertible notes due 2028 (69% of total outstanding) for cash equal to principal plus newly issued common stock, reducing debt from $33.5M to $10.5M

  Item 8.01 verify on EDGAR →
• high

  Stock portion of exchange will be priced using 21-day volume-weighted average starting June 11, 2026, meaning existing shareholders will face dilution from new share issuance

  Item 8.01 verify on EDGAR →
• medium

  Transaction expected to close around July 15, 2026, subject to customary conditions; company using existing cash to fund the $23M cash component

  Item 8.01 verify on EDGAR →